Debio 1143 and High-Dose Cisplatin Chemoradiotherapy in High-Risk Locoregionally Advanced SCCHN
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Debio 1143 and High-Dose Cisplatin Chemoradiotherapy in High-Risk Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Double-Blind, Multicentre, Randomised, Phase 2 Study
Lancet Oncol 2020 Aug 03;[EPub Ahead of Print], XS Sun, Y Tao, C Le Tourneau, Y Pointreau, C Sire, MC Kaminsky, A Coutte, M Alfonsi, P Boisselier, L Martin, J Miroir, JF Ramee, JP Delord, F Clatot, F Rolland, J Villa, N Magne, O Elicin, E Gherga, F Nguyen, C Lafond, G Bera, V Calugaru, L Geoffrois, B Chauffert, A Zubel, C Zanna, S Brienza, P Crompton, E Rouits, K Gollmer, S Szyldergemajn, J BourhisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.